Company profile for Sosei Group Corporation

PharmaCompass

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

Sosei Heptares is an international biopharmaceutical group focused on the design and development of new medicines originating from its proprietary GPCR-targeted StaR® technology and Structure-Based Drug Design platform capabilities. We are advancing a broad and deep pipeline of partnered and in-house drug candidates in multiple therapeutic areas including neurology, immuno-oncology, gastroenterology, inflammation and rare/spe...
Sosei Heptares is an international biopharmaceutical group focused on the design and development of new medicines originating from its proprietary GPCR-targeted StaR® technology and Structure-Based Drug Design platform capabilities. We are advancing a broad and deep pipeline of partnered and in-house drug candidates in multiple therapeutic areas including neurology, immuno-oncology, gastroenterology, inflammation and rare/specialty diseases.

List your booth number for exhibitions, ask us

CONTACT DETAILS

Click the arrow to open the dropdown
Country
Country
Japan
Address
Address
PMO Hanzomon 11F 2-1 Kojimachi, Chiyoda-ku Tokyo 102-0083
Telephone
Telephone
+81 (0)3 5210 3290
Linkedin
Linkedin
youtube
YouTube
Twitter
Twitter

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Events

Webinars & Exhibitions

Default Event

DDL Conference

Not Confirmed

envelop Contact Supplier

DDL Conference

Post an Enquiry

Meeting

Digital content

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more

https://www.globenewswire.com/news-release/2025/11/19/3190705/0/en/Nxera-Introduces-Employee-Stock-Ownership-Plan-J-ESOP-for-Employees-Residing-in-Japan.html

GLOBENEWSWIRE
19 Nov 2025

https://www.globenewswire.com/news-release/2025/11/17/3188823/0/en/Nxera-Announces-Focused-Restructuring-to-Enhance-Path-to-Profitability.html

GLOBENEWSWIRE
17 Nov 2025

https://www.globenewswire.com/news-release/2025/11/17/3188831/0/en/Nxera-Pharma-Shares-Video-Interviews-with-Major-Shareholders-on-Its-Official-YouTube-Channel.html

GLOBENEWSWIRE
17 Nov 2025

https://www.globenewswire.com/news-release/2025/10/31/3178105/0/en/Nxera-Pharma-Receives-a-Manufacturing-Approval-Partial-Amendment-Regarding-the-Addition-of-a-Manufacturing-Site-in-Asia-for-QUVIVIQ-25-and-50-mg.html

GLOBENEWSWIRE
31 Oct 2025

https://www.globenewswire.com/news-release/2025/10/31/3178104/0/en/Nxera-Pharma-Operational-Highlights-and-Consolidated-Results-for-the-Third-Quarter-and-First-Nine-Months-of-2025.html

GLOBENEWSWIRE
31 Oct 2025

https://www.globenewswire.com/news-release/2025/10/31/3178131/0/en/Nxera-s-President-CEO-to-Participate-in-a-Fireside-Chat-at-the-Jefferies-London-Healthcare-Conference-2025.html

GLOBENEWSWIRE
31 Oct 2025

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty